What changed
$KMX — AVOID 📊 | 6 MONTHS THESIS
🎯 FQ1 FY2027 (ends May) | reported Jun 17 | Rev $8.0B | EPS $1.31 vs $0.94 🟢
💡 Consensus expected a weak quarter, and the beat was 38.8%. The market now prices in sustained improvement, but we see a return to normalised earnings. The gap is between the beat‑driven optimism and the underlying weak fundamentals.
📉 Reward/risk: 3.7:1
🏢 Business Quality: 3/10
📊 Valuation: rich — base target $44.43 on 14.7x P/E is 16% below current price; even the bull case ($83.41 on 27.6x) requires heroic assumptions.
🔮 Catalyst: Q2 FY2027 earnings (approx. Sep 2026)
💰 Entry: $52.76, stop $55.0, target $44.43
⚖️ Avoid KMX — a 38.8% EPS beat does not make a quality stock, and the base target of $44.43 implies 16% downside from here, giving a 0.3:1 reward/risk that fails the 2:1 threshold.